5,440 Shares in Lantheus Holdings, Inc. $LNTH Purchased by Savant Capital LLC

Savant Capital LLC acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 5,440 shares of the medical equipment provider’s stock, valued at approximately $362,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. M&T Bank Corp acquired a new stake in shares of Lantheus in the fourth quarter valued at approximately $370,950,000. Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of Lantheus in the third quarter valued at approximately $11,443,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Lantheus by 73.4% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,452 shares of the medical equipment provider’s stock valued at $23,001,000 after purchasing an additional 189,814 shares during the period. William Blair Investment Management LLC increased its stake in shares of Lantheus by 46.7% in the third quarter. William Blair Investment Management LLC now owns 574,681 shares of the medical equipment provider’s stock valued at $29,475,000 after purchasing an additional 183,059 shares during the period. Finally, TD Asset Management Inc increased its stake in shares of Lantheus by 25.0% in the third quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock valued at $40,568,000 after purchasing an additional 158,358 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ LNTH opened at $100.98 on Friday. Lantheus Holdings, Inc. has a 12 month low of $47.25 and a 12 month high of $104.00. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The firm has a market capitalization of $6.57 billion, a PE ratio of 24.33 and a beta of -0.03. The company’s 50 day simple moving average is $88.01 and its 200 day simple moving average is $74.96.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. During the same quarter last year, the business earned $1.53 earnings per share. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 4.42 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. William Blair restated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. B. Riley Financial restated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Mizuho raised their price target on shares of Lantheus from $100.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, May 27th. Truist Financial restated a “buy” rating and issued a $115.00 price target (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $101.86.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.